|
Hardman & Co Research
Hardman & Co Video Event | Shield Therapeutics (STX) Investor Forum We are delighted to announce that Shield Therapeutics (STX) will be presenting at Hardman & Co's upcoming Investor Forum at 3:00pm this Thursday 14 November 2024. to secure your place and submit questions. A commercial-stage pharmaceutical company, Shield Therapeutics is strategically positioned to address the significant unmet medical needs of patients suffering from iron deficiency. Since launching in the US in July 2021, Shield, alongside its partner Viatris, has successfully elevated physician awareness of ACCRUFeR®, a unique oral treatment for iron deficiency. This concerted effort has driven substantial sales growth. Diligent cost management underpins management’s confidence that its cash position, combined with anticipated growth, will support the trajectory toward cashflow breakeven.
This interactive online Investor Forum comes at a crucial time. Presenting companies will address how their growth strategies and opportunity pipelines are set to perform in the post-budget environment, exploring the potential impacts and opportunities arising from the latest economic measures. The Forum promises to deliver valuable insights into how these businesses plan to leverage market conditions to sustain and drive growth. This webinar represents a key communication channel for investors learn about company strategy and progress. All investors, whether existing shareholders or not, are invited to watch the presentation and take part in the Q&A session afterwards. There is no charge for attending. Investors are encouraged to submit their questions when registering or during the event. A recording of the webinar will be available on the Hardman & Co website shortly after the event for those who cannot attend the live presentation.
Register here: To be first in the know about Hardman & Co’s latest digital events, subscribe to the mailing list . Our video events are designed to share the latest sector insights and company investment cases from our corporate clients and our expert team of analysts. Click to subscribe to the Hardman Talks channel on YouTube. Hardman & Co | 9 Bonhill Street | London | EC2A 4DJ | Hardman & Co Research can be accessed for free after MiFID II. About Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors’ understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies’ profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case. Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.
Dissemination of a CORPORATE NEWS, transmitted by EQS Group. |
2027145 11-Nov-2024
